I. Introduction
In May of 2018,
the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right
to Try Act of 2017 (“Right to Try Act”) was signed into law in order to
“authorize the use of unapproved medical products by patients diagnosed with a
terminal illness” as an “alternative pathway alongside, existing expanded
access policies of the Food and Drug Administration [(“FDA”)]. . . .”[1] While drafting the law, questions arose over
what types of diseases and conditions would be covered by the Right to Try Act
and whether those differed from existing laws allowing access to
investigational drugs.[2]
Given that nearly
45,000 Americans die of suicide each year,[3]
and that people with severe mental illnesses have a twenty-times higher risk of
suicide than the general population,[4]
such questioning by the drafters begs another: Does the Right to Try Act allow
patients with severe mental illnesses access to experimental drugs absent a
comorbid physical condition?